IRCCS Casa Sollievo della Sofferrenza opera di San Pio da Pietrelcina

Informazioni aggiuntive

• Pubblicazioni Scientifiche:

  Totale pubblicazioni a partire dal 2011: 69

  
  

  Anno

  2018; (): Outcome in ulcerative colitis after switch from adalimumab/golimumab to infliximab: A multicenter retrospective study. Viola A, Pugliese D, Renna S, Furfaro F, Caprioli F, D'Incà R, Bossa F, Mazza S, Costantino G, Fantini M, Fiorino G, Alibrandi A, Orlando A, Armuzzi A, Fries W

  2018; 10(): 75 Promoter methylation of the MGAT3 and BACH2 genes correlates with the composition of the immunoglobulin G glycome in inflammatory bowel disease. Klasić M, Markulin D, Vojta A, Samaržija I, Biruš I, Dobrinić P, Ventham NT, Trbojević-Akmačić I, Šimurina M, Štambuk J, Razdorov G, Kennedy NA, Satsangi J, Dias AM, Pinho S, Annese V, Latiano A, D'Inca R, IBD consortium., Lauc G, Zoldoš V

  2018; 12(6): 687-694 Addition of Granulocyte/Monocyte Apheresis to Oral Prednisone for Steroid-dependent Ulcerative Colitis: A Randomized Multicentre Clinical Trial. Domènech E, Panés J, Hinojosa J, Annese V, Magro F, Sturniolo GC, Bossa F, Fernández F, González-Conde B, García-Sánchez V, Dignass A, Herrera JM, Cabriada JL, Guardiola J, Vecchi M, Portela F, Ginard D, ATTICA Study Group by the Grupo Español de T

  2018; 155(3): 829-843 Plasma N-Glycan Signatures Are Associated With Features of Inflammatory Bowel Diseases. Clerc F, Novokmet M, Dotz V, Reiding KR, de Haan N, Kammeijer GSM, Dalebout H, Bladergroen MR, Vukovic F, Rapp E, IBD-BIOM Consortium., Targan SR, Barron G, Manetti N, Latiano A, McGovern DPB, Annese V, Lauc G, Wuhrer M

  2018; (): Unmet needs of Italian physicians managing patients with inflammatory bowel disease. Bezzio C, Imperatore N, Armuzzi A, Rizzello F, Manes G, Bossa F, Calabrese E, Caprioli F, Daperno M, Mocciaro F, Orlando A, Papi C, Rispo A, Saibeni S, Italian Group for Inflammatory Bowel Disease (IG-IBD).

  2018; (): The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy. Armuzzi A, Fiorino G, Variola A, Manetti N, Fries W, Orlando A, Maconi G, Bossa F, Cappello M, Biancone L, Cantoro L, Costa F, D'Incà R, Lionetti P, Principi M, Castiglione F, Annunziata ML, Di Sabatino A, Di Girolamo M, Terpin MM, Cortelezzi CC, Saibeni

  World J Gastrointest Pharmacol Ther 2017; 8(2): 131-136 Clinical and economic impact of infliximab one-hour infusion protocol in patients with inflammatory bowel diseases: A multicenter study. Viola A, Costantino G, Privitera AC, Bossa F, Lauria A, Grossi L, Principi MB, Della Valle N, Cappello M

  2017; 49(10): 1110-1114 Nurse in patients' health status assessment: Data from a pilot study assessing agreement among nurse and gastroenterologist in computing IBD-clinical scores. Mocciaro F, Pecoraro GM, Di Mitri R, Scimeca D, Bossa F, Russo G, Martino G, Costanza V, Profita MA, Orlando C, Profeta G, Tinè F

  2017; 49(4): 338-358 Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Biancone L, Annese V, Ardizzone S, Armuzzi A, Calabrese E, Caprioli F, Castiglione F, Comberlato M, Cottone M, Danese S, Daperno M, D'Incà R, Frieri G, Fries W, Gionchetti P, Kohn A, Latella G, Milla M, Orlando A, Papi C, Petruzziello C, Riegler G, Rizze

  2017; 11(5): 556-561 Training Programs on Endoscopic Scoring Systems for Inflammatory Bowel Disease Lead to a Significant Increase in Interobserver Agreement Among Community Gastroenterologists. Daperno M, Comberlato M, Bossa F, Armuzzi A, Biancone L, Bonanomi AG, Cosintino R, Lombardi G, Mangiarotti R, Papa A, Pica R, Grassano L, Pagana G, D'Incà R, Orlando A, Rizzello F, IGIBDEndo Group.

  2017; 23(2): 233-243 The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar. Fiorino G, Manetti N, Armuzzi A, Orlando A, Variola A, Bonovas S, Bossa F, Maconi G, D'Incà R, Lionetti P, Cantoro L, Fries W, Annunziata ML, Costa F, Terpin MM, Biancone L, Cortelezzi CC, Amato A, Ardizzone S, Danese S, Guidi L, Rizzuto G, Massella A, A

  2017; 18(7): Functional Implications of MicroRNAs in Crohn's Disease Revealed by Integrating MicroRNA and Messenger RNA Expression Profiling. Palmieri O, Creanza TM, Bossa F, Latiano T, Corritore G, Palumbo O, Martino G, Biscaglia G, Scimeca D, Carella M, Ancona N, Andriulli A, Latiano A

  2017; 12(1): e0168821 Crohn's Disease Localization Displays Different Predisposing Genetic Variants. Palmieri O, Bossa F, Valvano MR, Corritore G, Latiano T, Martino G, D'Incà R, Cucchiara S, Pastore M, D'Altilia M, Scimeca D, Biscaglia G, Andriulli A, Latiano A

  2016; : A Polymorphism of the Tnf-? Gene Promotes Steroid-Resistance In patients with Inflammatory Bowel Disease Palmieri O., Latiano A., Bossa F., Valvano M.R., D'incà R., Corritore G., Latiano T., Andriulli A., Annese V.

  2016; (): Training Programs on Endoscopic Scoring Systems for Inflammatory Bowel Disease Lead to a Significant Increase in Interobserver Agreement Among Community Gastroenterologists. Daperno M, Comberlato M, Bossa F, Armuzzi A, Biancone L, Bonanomi AG, Cosintino R, Lombardi G, Mangiarotti R, Papa A, Pica R, Grassano L, Pagana G, D'Incà R, Orlando A, Rizzello F, IGIBDEndo Group.

  2016; (): Disease patterns in late-onset ulcerative colitis: Results from the IG-IBD "AGED study". Fries W, Viola A, Manetti N, Frankovic I, Pugliese D, Monterubbianesi R, Scalisi G, Aratari A, Cantoro L, Cappello M, Samperi L, Saibeni S, Casella G, Mocci G, Rea M, Furfaro F, Contaldo A, Magarotto A, Calella F, Manguso F, Inserra G, Privitera AC, Princ

  2016; 6(): 31549 Gene expression of muscular and neuronal pathways is cooperatively dysregulated in patients with idiopathic achalasia. Palmieri O, Mazza T, Merla A, Fusilli C, Cuttitta A, Martino G, Latiano T, Corritore G, Bossa F, Palumbo O, Muscarella LA, Carella M, Graziano P, Andriulli A, Latiano A

  2016; 28(4): 581-91 Bloating is associated with worse quality of life, treatment satisfaction, and treatment responsiveness among patients with constipation-predominant irritable bowel syndrome and functional constipation. Neri L, Iovino P, Laxative Inadequate Relief Survey (LIRS) Group

  2016; (): Discontinuation of Infliximab in Patients With Ulcerative Colitis is Associated With Increased Risk of Relapse: A Multinational Retrospective Cohort Study. Fiorino G, Cortes PN, Ellul P, Felice C, Karatzas P, Silva M, Lakatos PL, Bossa F, Ungar B, Sebastian S, Furfaro F, Karmiris K, Katsanos KH, Muscat M, Christodoulou DK, Maconi G, Kopylov U, Magro F, Mantzaris GJ, Armuzzi A, Boscà-Watts MM, Ben-Horin S, Bo

  2016; (): Transperineal ultrasonography: First level exam in IBD patients with perianal disease. Terracciano F, Scalisi G, Bossa F, Scimeca D, Biscaglia G, Mangiacotti M, Valvano MR, Perri F, Simeone A, Andriulli A

  2016; 43(1): 174-5 Letter: cytomegalovirus colitis in a patient treated with ipilimumab for metastatic melanoma. Bossa F, Perri F, Niro G, Parente P, Graziano P, Andriulli A

  2016; (): Infliximab Reduces Endoscopic, but not Clinical, Recurrence of Crohn's Disease Following Ileocolonic Resection. Regueiro M, Feagan BG, Zou B, Johanns J, Blank MA, Chevrier M, Plevy S, Popp J, Cornillie FJ, Lukas M, Danese S, Gionchetti P, Hanauer SB, Reinisch W, Sandborn WJ, Sorrentino D, Rutgeerts P, PREVENT Study Group

  2015; (): Methotrexate is not Superior to Placebo in Inducing Steroid-free Remission, but Induces Steroid-free Clinical Remission in a Larger Proportion of Patients with Ulcerative Colitis. Carbonnel F, Colombel JF, Filippi J, Katsanos KH, Peyrin-Biroulet L, Allez M, Nachury M, Novacek G, Danese S, Abitbol V, Bossa F, Moreau J, Bommelaer G, Bourreille A, Fumery M, Roblin X, Reinisch W, Bouhnik Y, Brixi H, Seksik P, Malamut G, Färkkilä M, Cou

  2015; : e257 Whole exome sequencing of very early onset ulcerative colitis patients identifies new variants in candidate genes Palmieri O., Aloi M., Prudente S., Mazza T., Stronati L., Corritore G., Latiano T., Bossa F., Andriulli A., Cucchiara S., Latiano A.

  2015; 24(7): 1597-605 Confirmatory factor analysis of the Patient Assessment of Constipation-Symptoms (PAC-SYM) among patients with chronic constipation. Neri L, Conway PM, Basilisco G, Laxative Inadequate Relief Survey (LIRS) Group

  2015; (): 1-14 Systematic analysis of circadian genes using genome-wide cDNA microarrays in the inflammatory bowel disease transcriptome. Palmieri O, Mazzoccoli G, Bossa F, Maglietta R, Palumbo O, Ancona N, Corritore G, Latiano T, Martino G, Rubino R, Biscaglia G, Scimeca D, Carella M, Annese V, Andriulli A, Latiano A

  2015; (): Genome-wide Pathway Analysis Using Gene Expression Data of Colonic Mucosa in Patients with Inflammatory Bowel Disease. Palmieri O, Creanza TM, Bossa F, Palumbo O, Maglietta R, Ancona N, Corritore G, Latiano T, Martino G, Biscaglia G, Scimeca D, De Petris MP, Carella M, Annese V, Andriulli A, Latiano A

  2015; 372(12): 1104-13 Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease. Monteleone G, Neurath MF, Ardizzone S, Di Sabatino A, Fantini MC, Castiglione F, Scribano ML, Armuzzi A, Caprioli F, Sturniolo GC, Rogai F, Vecchi M, Atreya R, Bossa F, Onali S, Fichera M, Corazza GR, Biancone L, Savarino V, Pica R, Orlando A, Pallone F

  2014; (): Randomised controlled trial of mesalazine in IBS. Barbara G, Cremon C, Annese V, Basilisco G, Bazzoli F, Bellini M, Benedetti A, Benini L, Bossa F, Buldrini P, Cicala M, Cuomo R, Germanà B, Molteni P, Neri M, Rodi M, Saggioro A, Scribano ML, Vecchi M, Zoli G, Corinaldesi R, Stanghellini V

  2014; (): Patient and physician views on the quality of care in inflammatory bowel disease: Results from SOLUTION-1, a prospective IG-IBD study. Bortoli A, Daperno M, Kohn A, Politi P, Marconi S, Monterubbianesi R, Castiglione F, Corbellini A, Merli M, Casella G, D'Incà R, Orlando A, Bossa F, Doldo P, Lecis P, Valpiani D, Danese S, Comberlato M, on behalf of Italian Group for the study of Inflamma

  2014; (): Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease. Annese V, Vecchi M, on behalf of the Italian Group for the Study of IBD (IG-IBD), IG-IBD Governing Board, IG-IBD Governing Board

  2014; (): Inter-observer agreement in endoscopic scoring systems: Preliminary report of an ongoing study from the Italian Group for Inflammatory Bowel Disease (IG-IBD). Daperno M, Comberlato M, Bossa F, Biancone L, Bonanomi AG, Cassinotti A, Cosintino R, Lombardi G, Mangiarotti R, Papa A, Pica R, Rizzello F, D'Incà R, Orlando A

  2014; 46S: S78 Infliximab in steroid-dependent ulcerative colitis: lack of predictive factors for response in a large multicenter series M. Cappello, M. Mazza, G. Costantino, W. Fries, A.C. Privitera, M. Mastronardi, Bossa F., A. Rispo, F. Castiglione, A. Lauria, N. Buccianti, R. Marasco, L. Grossi, M.B. Principi, P.L. Almasio

  Inflammatory Bowel Diseaes - 9th Congress of ECCO 2014; : P452 Increasing interobserver agreement on IBD endoscopic scoring systems: results from the IGIBDEndo educational program Daperno M., Comberlato M., Bossa F., Bonanomi A.G., Lombardi G., Biancone L., Cosintino R., D'Incà R., Cassinotti A., Mangiarotti R., Papa A., Pica R., Rizzello F., Armuzzi A., Orlando A., on behalf of IG-IBD

  Inflammatory Bowel Diseaes - 9th Congress of ECCO 2014; : P629 Epidemiological features and disease related concerns of a large cohort of Italian patients with active Crohn’s disease Armuzzi A., Rigler G., Vecchi M., Baldoni M., Costa F., Fortuna M., Furfaro F., Iaquinto G., Paese P., Papi C., Rizzello F., Tornatore V., Bossa F.

  Inflammatory Bowel Diseaes - 9th Congress of ECCO 2014; : P447 Infliximab in the treatment of moderate-to-severe ulcerative colitis: Results of a large multicenter Italian survey Cappello M., Mazza M., Costantino G., Fries W., Privitera A.C., Mastronardi M., Bossa F., Rispo A., Castiglione F., Lauria A., Buccianti N., Marasco R., Grossi L., Principi M.B.

  2014; (): Early post-operative endoscopic recurrence in Crohn's disease patients: Data from an Italian Group for the study of inflammatory bowel disease (IG-IBD) study on a large prospective multicenter cohort. Orlando A, Mocciaro F, Renna S, Scimeca D, Rispo A, Lia Scribano M, Testa A, Aratari A, Bossa F, Tambasco R, Angelucci E, Onali S, Cappello M, Fries W, D'Incà R, Martinato M, Castiglione F, Papi C, Annese V, Gionchetti P, Rizzello F, Vernia P, Biancone L,

  2014; 75(4): 364-9 Impact of genetic polymorphisms on the pathogenesis of idiopathic achalasia: Association with IL33 gene variant. Latiano A, Palmieri O, Bossa F, Latiano T, Corritore G, De Santo E, Martino G, Merla A, Valvano MR, Cuttitta A, Mazza T, Annese V, Andriulli A

  2013; 45S: S80 Early post-operative endoscopic recurrence in Crohn’s disease: data from a large prospective italian multicenter cohort (an IG-IBD study) A. Orlando, F. Mocciaro, Scimeca D., A. Rispo, Scribano M.L., Testa A., Aratari A., Bossa F., Tambasco R., Angelucci E., Onali S., Cappello M., Fries W., D’Incà R., Martinato M., Castiglione F., Papi C., Annese V., Gionchetti P., Rizzello F., Vernia P., B

  2013; : S-436 (Su1237) A Retrospective Multicenter Survey on Infliximab Efficacy and Safety in Moderate-to-Severe and Steroid-Dependent Ulcerative Colitis Cappello M., Mazza M., Costantino G., Fries W., Privitera A.C., Mastronardi M., Buccianti N., Castiglione F., R., Lauria A., Marasco R., Almasio P.L., Bossa F.

  2013; : S205 Infliximab in moderate-to-severe ulcerative colitis: efficacy and safety in a “real life” retrospective multicenter study from southern Italy Cappello M., Mazza M., Costantino G., Fries W., Privitera A.C., Mastronardi M., Bossa F. , Castiglione F., Rispo A., Lauria A., Buccianti N., Marasco R., Almasio P.L.

  2013; 45(9): 738-43 Adalimumab in active ulcerative colitis: A "real-life" observational study. Italian Group for the Study of Inflammatory Bowel Disease

  2013; 19(9): 1872-9 Erythrocytes-mediated Delivery of Dexamethasone 21-phosphate in Steroid-dependent Ulcerative Colitis: A Randomized, Double-blind Sham-controlled Study. Bossa F, Annese V, Valvano MR, Latiano A, Martino G, Rossi L, Magnani M, Palmieri O, Serafini S, Damonte G, De Santo E, Andriulli A

  2013; 8(4): e62144 Associations between Genetic Polymorphisms in IL-33, IL1R1 and Risk for Inflammatory Bowel Disease. Latiano A, Palmieri O, Pastorelli L, Vecchi M, Pizarro TT, Bossa F, Merla G, Augello B, Latiano T, Corritore G, Settesoldi A, Valvano MR, D'Incà R, Stronati L, Annese V, Andriulli A

  2013; 2013 - suppl 1: s 278 - p667 Dissecting the role of unfolded protein response pathway in inflammatory bowel disease: in silico mRNA-miRNA co-expression analysis Palmieri O, Bossa F, Creanza MT, Latiano T, Corritore G, Scimeca D, Biscaglia G, Liuzzi VC, Anglani R, Carella M, Annese V, Andriulli A, Latiano A

  2012; (): Estimates of HCV-1 Patients Attaining RVR Following Dual Therapy with Peg-Interferon and Ribavirin. Andriulli A, Iacobellis A, Valvano MR, Spirito F, Ippolito A, Bossa F, Terracciano F, Fontana R, Niro G

  2012; 21(23): 5209-5221 Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants. Juran BD, Hirschfield GM, Invernizzi P, Atkinson EJ, Li Y, Xie G, Kosoy R, Ransom M, Sun Y, Bianchi I, Schlicht EM, Lleo A, Coltescu C, Bernuzzi F, Podda M, Lammert C, Shigeta R, Chan LL, Balschun T, Marconi M, Cusi D, Mason AL, Myers RP, Milkiewicz P, Od

  2012; 29(8): 994-1003 Association Study of a Polymorphism in Clock Gene PERIOD3 and Risk of Inflammatory Bowel Disease. Mazzoccoli G, Palmieri O, Corritore G, Latiano T, Bossa F, Scimeca D, Biscaglia G, Valvano MR, D'Incà R, Cucchiara S, Stronati L, Annese V, Andriulli A, Latiano A

  2012; 13(6): 461-468 Classical HLA-DRB1 and DPB1 alleles account for HLA associations with primary biliary cirrhosis. Invernizzi P, Ransom M, Raychaudhuri S, Kosoy R, Lleo A, Shigeta R, Franke A, Bossa F, Amos CI, Gregersen PK, Siminovitch KA, Cusi D, de Bakker PI, Podda M, Gershwin ME, Seldin MF, The Italian PBC Genetics Study Group

  2012; 18th Congress of Digestive Diseases - 44s P.05.13: s115-s116 Infliximab versus adalimumab in crohn's disease patients in daily clinical practice. A prospective single center experience_ Bossa F, Annese V, Scimeca D, Biscaglia G, Colombo E, Martino G, De Santo E, Andriulli A

  2012; 18th Congress of Digestive Diseases 44s: s68-s69 Adalimumab in active ulcerative colitis: a "real life" observation study_ Armuzzi A, Biancone L, Daperno M, Coli A, Annese V, Ardizzone S, Balestrieri P, Bossa F, Castiglione F, Cicala M, Danese S, D'Incà R, Dulbecco P, Feliciangeli G, Fries W, Genise S, Gionchetti P, Gozzi S, Kohn A, Lorenzetti R, Milla M, Onalli S, Orlando A,

  2012; 142, issue 5, s1, 868: s149-s150 Immunochip -Based Analysis of a Large IBD Case-Control Cohort Identities 50 Novel Loci, Refining Definitions of Disease Pathways Cho JH, IIBDGC, Latiano A, Bossa F, Palmieri O

  2012; 142,issue 5, s1, sa1887: s350-s351 Adalimumab in Activa Ulcerative Colitis: A"Real-Life" Observational Study Armuzzi A, Biancone L, Daperno M, Coli A, Annese V, Ardizzone S, Balestrieri P, Bossa F, Castiglione F, Cicala M, Danese S, D'Incà R, Dulbecco P, Feliciangeli G, Fries W, Genise S, Gionchetti P, Gozzi S, Kohn A, Lorenzetti R, Milla M, Onali S, Papi C, Pap

  2012; 142, issue 5, s1: s536 Interobserver Agreement in IBD Endoscopic Scoring: Preliminary Results of an Ongoing IG-IBD study Daperno M, Comberlato M, Bossa F, Biancone L, Bonanomi AG, Cassinotti A, Cosintino R, Lombardi G, Mangiarotti R, Papi C, Pica R, Rizzello F, D'Incà R

  2012; 44s-oc.12.3: s81 Early Post-operative endoscopic recurrence in crohn's disease in a large prospective italian multicente cohort Orlando A, Mocciaro F, Scimeca D, Rispo A, Scribano ML, Testa A, Aratari A, Bossa F, Tambasco R, Angelucci E, Onali S, Cappello M, Fries W, D'Incà R, Martinato M, Castiglione F, Papi C, Annese V, Gionchetti P, Rizzello F, Vernia P, Biancone L, Perricone G

  2012; 44s-oc.12.2: s81 Patients' and physicians' views on quality of care in inflammatory bowel disease: initial results from an ongoing prospective IG-IBD study Bortoli A, Daperno M, Kohn A, Comberlato M, Politi P, Castiglione F, Valpiani D, D'Incà R, Marconi S, Merli M, Boni F, Casella G, Orlando A, Bossa F, Doldo P

  2012; 6-p230: s101 Adalimumab in active ulcerative colitis: A "real-life" observational study Armuzzi A, Biancone L, Daperno M, Coli A, Avvese V, Ardizzone S, Balestrieri P, Bossa F, Castiglione F, Cicala M, Danese S, D'Incà R, Dulbecco P, Feliciangeli G, Feliciangeli G, Fries W, Genise S, Gionchetti P, Gozzi S, Kohn A, Lorenzetti R, Milla M, Ona

  2012; 6-p181: s81-s82 Patients’ and physicians’ views on quality of care in inflammatory bowel disease: Initial results from an ongoing prospective IG-IBD study Bortoli A, Kohn A, Daperno M, D'Incà R, Orlando A, Bossa F, Doldo P, Comberlato M, Politi P, Valpiani D

  2012; 6-p291: s126 Infliximab versus adalimumab in Crohn's disease patients in daily clinical practise. A prospective single center experience Bossa F, Annese V, Scimeca D, Biscaglia G, Colombo E, Martino G, De Santo E, Andriulli A

  2012; 6-p289: s125 Concordance in IBD endoscopic scoring requires expertise and training: Preliminary results of an ongoin IG-IBD study Daperno M, Comberlato M, Bossa F, Biancone L, Bonanomi A, Cassinotti A, Cosintino R, Lombardi G, Mangiarotti R, Orlando A, Papa A, Pica R, Rizzello F, D'Incà R

  2012; 6-p448: s187 Polymorphism in IL-33, IL1RL1 genes and risk of inflammatory bowel disease Latiano A, Palmieri O, Pastorelli L, Vecchi M, Pizarro T, Bossa F, Merla G, Augello B, Valvano MR, D'Incà R, Cucchiara S, Annese V, Andriulli A,

  2012; 44s: s80 Interobserver agreement in IBD scores requires expertise and education: preliminary results from an ongoing IG-IBD study Daperno M, Comberlato M, Bossa F, Biancone L, Bonanomi A, Cassinotti A, Cosintino R, Lombardi G, Mangiarotti R, Orlando A, Papa A, Pica R, Rizzello F, Incà RD, Dincà R, IG-IBD

  2012; 6(5): 563-70 Neuroimmune interactions in patients with inflammatory bowel diseases: Disease activity and clinical behavior based on Substance P serum levels. Tavano F, di Mola FF, Latiano A, Palmieri O, Bossa F, Valvano MR, Latiano T, Annese V, Andriulli A, di Sebastiano P

  2012; 56: s427 A substantial proportion of naive HCV-1 infected patients with chronic infection may benefit from current standard therapy with PEG-interferon and ribavirin Andriulli A, Valvano MR, Spirito F, Ippolito A, Iacobellis A, Bossa F, Terracciano F, Niro G

  2011; 6(7): e22688 Investigation of multiple susceptibility loci for inflammatory bowel disease in an Italian cohort of patients. Latiano A, Palmieri O, Latiano T, Corritore G, Bossa F, Martino G, Biscaglia G, Scimeca D, Valvano MR, Pastore M, Marseglia A, D'Incà R, Andriulli A, Annese V

  2011; AGA Abstracts: S-272 Dissection of the Crohn's Disease Transcriptome of 71 Loci Using Genome-Wide Microarrays Orazio Palmieri, Anna Latiano, Rosalia Maglietta, Orazio Palumbo, Giuseppe Corritore, Tiziana Latiano, Giuseppina Martino, Massimo Carella, Nicola Ancona, Fabrizio Bossa, Angelo Andriulli, Vito Annese

  2011; : S161 Whole-transcript human gene expression pathway analysis in Crohn's disease O. Palmieri, A. Latiano, R. Maglietta, B. Fabrizio, D. Scimeca, G. Biscaglia, O. Palumbo, M. Carella, N. Ancona, A. Andriulli, V. Annese

  2011; (): IL23R, ATG16L1, IRGM, OCTN1, and OCTN2 mRNA expression in inflamed and noninflamed mucosa of IBD patients. Palmieri O, Latiano A, Scimeca D, Bossa F, Corritore G, Latiano T, Andriulli A, Annese V

  2011; (): Dissecting the mucosal expression of human leucine-rich repeat family genes in inflammatory bowel disease patients. Palmieri O, Latiano A, Maglietta R, Palumbo O, Carella M, Ancona N, Bossa F, Andriulli A, Annese V

  {accordionfaq faqid=accordion3 faqclass="lightnessfaq defaulticon headerbackground headerborder contentbackground contentborder round5" active=0}